Scale -


  • Revenue is 862 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 15 %; in Bottom Quartile
  • Ebitda is 143 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 13 %; in Bottom Quartile
  • PBT is 23.08 Rs Cr; Continuous Growth over 3 years; Annual Decline is -18 %; in Bottom Quartile
  • Quarterly Revenue is 250 Rs Cr; Continuous Growth over 3 Quarters; in Bottom Quartile
  • Quarterly Ebitda is 48.23 Rs Cr; Continuous Growth over 3 Quarters
  • PAT is 28.47 Rs Cr; Annual Decline is -18 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -11 %

Profitability -


  • Quarterly Ebitda Margin is 19 %; Continuous Growth over 3 Quarters
  • Quarterly Profit margin is 7 %; Continuous Growth over 3 Quarters; in Bottom Quartile
  • PAT Margin is 3.3 %; Annual Decline is -26 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -23 %

Return -


  • ROCE is 6.76 %; Annual Decline is -39 %; in Bottom Quartile; 5 Year CAGR is -15 %
  • ROA is 0.99 %; Annual Decline is -50 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -35 %
  • ROE is 3.52 %; Annual Decline is -20 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -23 %
  • Asset Turnover is 37 %; Annual Decline is -23 %; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -16 %

Efficiency -


  • Operating cash flow is -231 Rs Cr; Annual Decline is -218 %; in Bottom Quartile
  • Current Ratio is 1.17; Continuous Decline over 3 years; in Bottom Quartile
  • Quick Ratio is 0.69; in Bottom Quartile
  • Inventory Turnover Ratio is 1.96; in Bottom Quartile

Solvancy -


  • Contingent Liabilities is 0 Rs Cr; Annual Decline is -100 %; Continuous Decline over 3 years; in Bottom Quartile
  • Long term Debt is 1.85 Rs Cr; Continuous Decline over 3 years
  • Debt/Equity is 1.63; Annual Growth is 126 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 38 %
  • Total Debt is 32 Rs Cr; Annual Growth is 55 %; Continuous Growth over 3 years; 5 Year CAGR is 24 %

Quality -


  • Change in Inventories/Total Expenses is -21 %; Annual Decline is -79 %; in Bottom Quartile
  • Operating cashflow/ebitda is -161 %; Annual Decline is -216 %; in Bottom Quartile
  • Operating cashflow/PAT is -8.13 %; Annual Decline is -244 %; in Bottom Quartile
  • Exceptional Items/PBT is 0 %; Annual Growth is 100 %; in Top Quartile
  • Current Tax/PAT is 63 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 30 %
  • Other Expenses/Total Expenses is 20 %; 5 Year CAGR is 50 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Neogen Chemicals NEOGEN Q2FY27 Earnings Conference Call
Neogen Chemicals to Consider Q2 Results and Rs 200 Crore Debt Redemption
Neogen Chemicals: Q2 ????????? **?200 ?????????** ???????????? ??????, ??????????????? ????
Neogen Chemicals Ltd. Estimates – NSE:NEOGEN
Neogen Chemicals Dividend 2026: ?1.00, Record Date 13 Aug
Neogen Chemicals Share Price Fall: Key Metrics and Context
Up 64% in 6 months already; should you still buy Neogen Chemicals? Antique sees 23% upside potential
Neogen Chemicals (NSEI:NEOGEN) Stock Forecast & Analyst Predictions
Neogen Chemicals (NEOGEN.NS) Slips 5.61% to ?2537.2 as Specialty Chemicals Stock Tests Key Support Zone
Neogen Chemicals
Neogen Chemicals share price jumps nearly 15% in 3 sessions | What's driving the rally, is more upside ahead?
Neogen Chemicals Share Price Rally: Why It Jumped 15% in 3 Days
Neogen Chemicals Limited Reports Non-Convertible Debentures Issued on Private Placement Basis with 2,000 Million Outstanding
Neogen Chemicals (NEOGEN.NS) Trades Flat at ?2,431.3 as Range Boundaries Come Into Focus
Neogen Chemicals Limited (NEOGEN.NS) Holds Steady Near ?2,431 as Specialty Chemicals Stock Consolidates
Neogen Chemicals Share Price rises 5.17%: valuation check